Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
by investors
|
| gptkbp:businessModel |
partnerships
licensing agreements therapeutic development |
| gptkbp:CEO |
Bart_Henderson
|
| gptkbp:clinicalTrials |
Phase 1
Phase 2 Phase 3 ongoing studies solid tumors biopharmaceutical company multiple myeloma positive results |
| gptkbp:collaborations |
hospitals
academic institutions research institutions biopharma companies |
| gptkbp:focus |
red cell therapeutics
|
| gptkbp:founded |
2013
|
| gptkbp:founder |
gptkb:Juan_Carlos_Izpisua_Belmonte
|
| gptkbp:funding |
venture capital
public offerings |
| gptkbp:future_plans |
enhance technology
expand pipeline increase collaborations |
| gptkbp:goal |
treating cancer
treating rare diseases treating autoimmune diseases |
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rubius Therapeutics
|
| gptkbp:investmentFocus |
institutional investors
private equity |
| gptkbp:leadership |
executive team
scientific advisory board |
| gptkbp:market |
oncology
hematology immunology |
| gptkbp:mission |
transforming patient care
|
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:platforms |
therapeutic applications
cell engineering RUBY platform |
| gptkbp:publications |
peer-reviewed journals
|
| gptkbp:regulatoryCompliance |
gptkb:FDA
EMA |
| gptkbp:research_focus |
genetic engineering
immunotherapy cell therapy |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
RUBY
|
| gptkbp:technology |
engineered red blood cells
|
| gptkbp:tributaryOf |
RUBY-300
RUBY-500 RUBY-700 |
| gptkbp:vision |
cell-based therapies
|